#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
How semaglutide works across the body
A 2026 review reads semaglutide through a systems medicine lens, tracing the GLP-1 receptor agonist from trial outcomes to the molecular mediators underneath.
Weight-loss drugs and hypertension
A Cochrane review of eight trials finds insufficient evidence that weight-loss drugs cut mortality or cardiovascular events in hypertensive patients.
Eating disorder screens predict GLP-1 use
A US survey of 1,309 adults links positive eating disorder screens to higher GLP-1 awareness and telehealth drug-seeking.
GLP-1 drugs improve ratio but cut muscle
A 2026 meta-analysis of 7 RCTs finds GLP-1 receptor agonists raise the lean-to-fat ratio while causing a 1.74 kg average absolute lean mass loss.
GLP-1 drugs and lung safety: what we know
A 2026 systematic review examines pulmonary adverse events with GLP-1 receptor agonists, from mild upper-airway infections to perioperative aspiration risk.
Semaglutide tied to lower seizure risk
A target trial emulation using the All of Us database found semaglutide users had roughly half the seizure risk of adults on other glucose-lowering drugs.
Semaglutide may protect joints via muscle
A 2026 mouse study reports that semaglutide restores muscle mitochondrial function, raises glutamine, and reduces cartilage inflammation.
Semaglutide CV edge over tirzepatide
A 47-trial meta-analysis finds semaglutide cuts MACE by 29% and CV death by 19%. Tirzepatide trends protective but lacks the trial base to confirm it.
Semaglutide vs SGLT2 inhibitors in MASLD
A propensity-matched TriNetX study compares semaglutide against SGLT2 inhibitors in patients with fatty liver disease and type-2 diabetes.
Weight-loss drugs and fertility: the data
A meta-analysis of seven trials finds orlistat and semaglutide may boost ovulation and pregnancy rates in women with obesity.
ACP review: which obesity drugs pay off?
A new ACP systematic review rates tirzepatide high-value but flags poor study quality across all obesity drug cost models.
ACP: tirzepatide, semaglutide first-line
A living ACP guideline published 16 June 2026 places tirzepatide and semaglutide first among pharmacologic obesity treatments for US outpatient adults.